Nuwellis Announces Publication Of Study In Current Problems in Cardiology Demonstrating The Aquadex Ultrafiltration Therapy Reduced 60 Day Hospital Readmission Rates For ADHF Patients
Portfolio Pulse from Benzinga Newsdesk
Nuwellis has announced a study published in Current Problems in Cardiology, showing that their Aquadex Ultrafiltration Therapy significantly reduced 60-day hospital readmission rates for patients with acute decompensated heart failure (ADHF).
August 27, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuwellis' Aquadex Ultrafiltration Therapy has been shown to reduce 60-day hospital readmission rates for ADHF patients, potentially boosting the company's reputation and demand for its product.
The study's positive results could enhance Nuwellis' market position and increase demand for Aquadex, likely leading to a positive impact on NUWE's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100